These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32314417)

  • 21. De Novo and Recurrent Thrombotic Microangiopathy After Renal Transplantation: Current Concepts in Management.
    Abbas F; Abbas SF
    Exp Clin Transplant; 2022 Jun; 20(6):549-557. PubMed ID: 34546154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.
    Schwimmer J; Nadasdy TA; Spitalnik PF; Kaplan KL; Zand MS
    Am J Kidney Dis; 2003 Feb; 41(2):471-9. PubMed ID: 12552512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.
    Shochet L; Kanellis J; Simpson I; Ta J; Mulley W
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():23-27. PubMed ID: 28176480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. De novo systemic atypical hemolytic uremic syndrome in an ABO-incompatible living kidney transplant recipient with a novel pathogenic CFHR1 gene mutation successfully treated with eculizumab: a case report.
    Li D; Wang W; Chen R; Wen J; Zhang M
    J Nephrol; 2022 Sep; 35(7):1895-1899. PubMed ID: 35852773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological risk and complement genetic evaluations in early onset de novo thrombotic microangiopathy after living donor kidney transplantation: A Japanese multicenter registry.
    Fujiyama N; Tasaki M; Harada H; Tsutahara K; Matsumoto A; Kamijo Y; Toyoda M; Iwami D; Inui M; Shirakawa H; Sugimura J; Saito M; Hotta K; Okumi M; Saito K; Watarai Y; Hidaka Y; Ohtani K; Inoue N; Wakamiya N; Habuchi T; Satoh S;
    Clin Exp Nephrol; 2023 Dec; 27(12):1010-1020. PubMed ID: 37634218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Incomplete thrombotic microangiopathy as a variant of hemolytic-uremic syndrome].
    Kozlovskaya NL; Chebotareva NV; Nikogosova AD; Demyanova KA; Varshavsky VA; Roshchupkina SV
    Ter Arkh; 2016; 88(6):77-79. PubMed ID: 27296266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
    Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
    Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series.
    Martins M; Bridoux F; Goujon JM; Meuleman MS; Ribes D; Rondeau E; Guerry MJ; Delmas Y; Levy B; Ducloux D; Kandel-Aznar C; Le Fur A; Garrouste C; Provot F; Gibier JB; Thervet E; Bruneval P; Rabant M; Karras A; Dragon Durey MA; Fremeaux-Bacchi V; Chauvet S
    Am J Kidney Dis; 2022 Sep; 80(3):341-352. PubMed ID: 35217094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Life-Threatening Diffuse Alveolar Hemorrhage and Graft Failure in Atypical Hemolytic Uremic Syndrome with C3 Gene Mutation following Kidney Transplant.
    Song JY; Oh SH; Kim Y
    Nephron; 2024; 148(7):474-479. PubMed ID: 38008090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
    Kistler AD
    Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa L; Espinosa M; Grinyó JM; Macía M; Mendizábal S; Praga M; Román E; Torra R; Valdés F; Vilalta R; Rodríguez de Córdoba S
    Nefrologia; 2015; 35(5):421-47. PubMed ID: 26456110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Better late than never: Diagnosis of recurrent atypical hemolytic uremic syndrome.
    Aaltonen S; Räisänen-Sokolowski A; Kaartinen K
    Clin Nephrol; 2023 Jul; 100(1):41-44. PubMed ID: 37114491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies.
    Maisons V; Duval A; Mesnard L; Frimat M; Fakhouri F; Grangé S; Servais A; Cartery C; Fauchier L; Coppo P; Titeca-Beauport D; Fage N; Delmas Y; Quérard AH; Seret G; Bobot M; Le Quintrec M; Ville S; von Tokarski F; Chauvet S; Wynckel A; Martins M; Schurder J; Barbet C; Sautenet B; Gatault P; Caillard S; Vuiblet V; Halimi JM;
    Kidney Int; 2024 May; 105(5):1100-1112. PubMed ID: 38431217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the role of the complement system, endothelial injury, and microRNAs in thrombotic microangiopathy after kidney transplantation.
    Aleš Rigler A; Večerić-Haler Ž; Arnol M; Perše M; Boštjančič E; Pleško J; Simčič S; Kojc N
    J Int Med Res; 2020 Dec; 48(12):300060520980530. PubMed ID: 33372813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis.
    Gonzalez Suarez ML; Thongprayoon C; Mao MA; Leeaphorn N; Bathini T; Cheungpasitporn W
    J Clin Med; 2019 Jun; 8(7):. PubMed ID: 31252541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome.
    Ono M; Ohashi N; Namikawa A; Katahashi N; Ishigaki S; Tsuji N; Isobe S; Iwakura T; Sakao Y; Tsuji T; Kato A; Fujigaki Y; Shimizu A; Yasuda H
    Intern Med; 2018 Jun; 57(11):1617-1623. PubMed ID: 29434134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.